clinical trial · NCT05606965
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
ModernaTX, Inc.·phase2·completed·n = 172
InfluenzamRNA-1010Egg-based Quadrivalent Influenza VaccineAdjuvanted Quadrivalent Influenza VaccineInactivated Influenza VaccinemRNA-1345mRNA-1045
brief summary
The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.
started
Nov 2, 2022
primary completion
Nov 13, 2025
completion
Nov 13, 2025
last updated
Nov 24, 2025
detailed description
The study consists of 3 parts. Part A of the study was conducted for the 2022-23 influenza season. Part B of the study was conducted in 2023-24 influenza season. Part C of the study will be conducted in 2024-25 influenza season.
official title
Phase 2, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 and Comparator Seasonal Influenza Vaccines in Healthy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol